Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions
In this podcast episode, listen to myeloma experts Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, provide their thoughts on optimal treatment for relapsed/refractory multiple myeloma.
Decera Clinical Education Oncology Podcast · Suzanne Lentzch MD PhD, Saad Usmani MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this podcast episode, Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:
- Selecting optimal triplet regimen after first relapse
- Sequencing treatment options after multiple relapses
- Managing patient expectations when selecting treatments
- Emerging treatment options for R/R MM
Presenters:
Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York
Saad Z. Usmani, MD, MBA, FACP
Clinical Professor of Medicine
Department of Hematologic Oncology & Blood Disorders
Division Chief
Plasma Cell Disorders Division
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina
Supported by educational grants from Amgen; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Oncopeptides.
Link to full program, including an downloadable slidesets and an on-demand webcast:
https://bit.ly/3gjr62p
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.